High serum uric acid (SUA) and triglyceride (TG) levels might promote high-cardiovascular risk phenotypes across the cardiometabolic spectrum. However, SUA predictive power in the presence of normal and high TG levels has never been investigated. We included 8124 patients from the URic acid Right for heArt Health (URRAH) study cohort who were followed for over 20 years and had no established cardiovascular disease or uncontrolled metabolic disease. All-cause mortality (ACM) and cardiovascular mortality (CVM) were explored by the Kaplan-Meier estimator and Cox multivariable regression, adopting recently defined SUA cut-offs for ACM (>= 4.7 mg/dL) and CVM (>= 5.6 mg/dL). Exploratory analysis across cardiometabolic subgroups and a sensitivity analysis using SUA/serum creatinine were performed as validation. SUA predicted ACM (HR 1.25 [1.12-1.40], p < 0.001) and CVM (1.31 [1.11-1.74], p < 0.001) in the whole study population, and according to TG strata: ACM in normotriglyceridemia (HR 1.26 [1.12-1.43], p < 0.001) and hypertriglyceridemia (1.31 [1.02-1.68], p = 0.033), and CVM in normotriglyceridemia (HR 1.46 [1.23-1.73], p < 0.001) and hypertriglyceridemia (HR 1.31 [0.99-1.64], p = 0.060). Exploratory and sensitivity analyses confirmed our findings, suggesting a substantial role of SUA in normotriglyceridemia and hypertriglyceridemia. In conclusion, we report that SUA can predict ACM and CVM in cardiometabolic patients without established cardiovascular disease, independent of TG levels.
Serum Uric Acid Predicts All-Cause and Cardiovascular Mortality Independently of Hypertriglyceridemia in Cardiometabolic Patients without Established CV Disease: A Sub-Analysis of the URic acid Right for heArt Health (URRAH) Study / Mengozzi, Alessandro; Pugliese, Nicola Riccardo; Desideri, Giovambattista; Masi, Stefano; Angeli, Fabio; Barbagallo, Carlo Maria; Bombelli, Michele; Cappelli, Federica; Casiglia, Edoardo; Cianci, Rosario; Ciccarelli, Michele; Cicero, Arrigo F G; Cirillo, Massimo; Cirillo, Pietro; Dell'Oro, Raffaella; D'Elia, Lanfranco; Ferri, Claudio; Galletti, Ferruccio; Gesualdo, Loreto; Giannattasio, Cristina; Grassi, Guido; Iaccarino, Guido; Lippa, Luciano; Mallamaci, Francesca; Maloberti, Alessandro; Masulli, Maria; Mazza, Alberto; Muiesan, Maria Lorenza; Nazzaro, Pietro; Palatini, Paolo; Parati, Gianfranco; Pontremoli, Roberto; Quarti-Trevano, Fosca; Rattazzi, Marcello; Reboldi, Gianpaolo; Rivasi, Giulia; Russo, Elisa; Salvetti, Massimo; Tikhonoff, Valerie; Tocci, Giuliano; Ungar, Andrea; Verdecchia, Paolo; Viazzi, Francesca; Volpe, Massimo; Borghi, Claudio; Virdis, Agostino. - In: METABOLITES. - ISSN 2218-1989. - 13:2(2023), pp. 1-15. [10.3390/metabo13020244]
Serum Uric Acid Predicts All-Cause and Cardiovascular Mortality Independently of Hypertriglyceridemia in Cardiometabolic Patients without Established CV Disease: A Sub-Analysis of the URic acid Right for heArt Health (URRAH) Study
Desideri, Giovambattista;Cianci, Rosario;Tocci, Giuliano;Volpe, Massimo;
2023
Abstract
High serum uric acid (SUA) and triglyceride (TG) levels might promote high-cardiovascular risk phenotypes across the cardiometabolic spectrum. However, SUA predictive power in the presence of normal and high TG levels has never been investigated. We included 8124 patients from the URic acid Right for heArt Health (URRAH) study cohort who were followed for over 20 years and had no established cardiovascular disease or uncontrolled metabolic disease. All-cause mortality (ACM) and cardiovascular mortality (CVM) were explored by the Kaplan-Meier estimator and Cox multivariable regression, adopting recently defined SUA cut-offs for ACM (>= 4.7 mg/dL) and CVM (>= 5.6 mg/dL). Exploratory analysis across cardiometabolic subgroups and a sensitivity analysis using SUA/serum creatinine were performed as validation. SUA predicted ACM (HR 1.25 [1.12-1.40], p < 0.001) and CVM (1.31 [1.11-1.74], p < 0.001) in the whole study population, and according to TG strata: ACM in normotriglyceridemia (HR 1.26 [1.12-1.43], p < 0.001) and hypertriglyceridemia (1.31 [1.02-1.68], p = 0.033), and CVM in normotriglyceridemia (HR 1.46 [1.23-1.73], p < 0.001) and hypertriglyceridemia (HR 1.31 [0.99-1.64], p = 0.060). Exploratory and sensitivity analyses confirmed our findings, suggesting a substantial role of SUA in normotriglyceridemia and hypertriglyceridemia. In conclusion, we report that SUA can predict ACM and CVM in cardiometabolic patients without established cardiovascular disease, independent of TG levels.File | Dimensione | Formato | |
---|---|---|---|
Mengozzi_Serum-Uric-Acid-Predicts-All-Caus_2023.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
2.66 MB
Formato
Adobe PDF
|
2.66 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.